Showing 3301-3310 of 5956 results for "".
- Lumata Health Raises $4 Million in Series A Funding to Scale its Human-Led, Intelligent Eye Care Management Platformhttps://modernod.com/news/lumata-health-raises-4-million-in-series-a-funding-to-scale-its-human-led-intelligent-eye-care-management-platform/2481201/Lumata Health announces $4 million in new venture funding to scale its impact throughout the United States. Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and h
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7
- UCI Team Demonstrates the Adult Brain has the Potential to Partially Recover from Inherited Blindnesshttps://modernod.com/news/uci-team-demonstrates-the-adult-brain-has-the-potential-to-partially-recover-from-inherited-blindness/2481173/A discovery about how some visually impaired adults could start to see offers a new vision of the brain’s possibilities. The finding that the adult brain has the potential to partially recover from inherited blindness comes from a
- Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a cor
- Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Greater Sensitivity than Dilated Examshttps://modernod.com/news/study-finds-eyenuk-artificial-intelligence-detects-diabetic-retinopathy-with-greater-sensitivity-than-dilated-exams/2481158/Eyenuk announced the publication of EyeArt validation results in Ophthalmology Science, a peer-reviewed journal of the American Academy of Ophthalmology. The study, titled “Artifici
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- Cellusion and Minaris Regenerative Medicine Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a letter of intent (LOI) of the manufacturing of CLS001 for a cor
- Study: Specialized Smart Soft Contact Lenses Can Address Global Issue of Glaucoma Diagnosis, Managementhttps://modernod.com/news/study-specialized-smart-soft-contact-lenses-can-address-global-issue-of-glaucoma-diagnosis-management/2481144/The vision of
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul
- Haag-Streit to Host a Series of Educational Webinars as Part of its Biometry Focus Month in Novemberhttps://modernod.com/news/haag-streit-to-host-a-series-of-educational-webinars-as-part-of-its-biometry-focus-month-in-november/2481139/Haag-Streit will host a variety of educational webinars as part of its Biometry Focus Month in November. This series of webinars will be delivered by a distinguished faculty consisting of notable key opinion leaders, complemented by Haag-Streit biometry product specialists. Hosted on Zo